Marker Therapeutics, Inc. (NasdaqCM: MRKR)
Health Care · Biotechnology · US
$1.50
+7.91% today · +7.8% 1Y
Marker Therapeutics, Inc. (NasdaqCM: MRKR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $23.18M and employs 5 people.
Over the last twelve months the share price has gained 7.8%, trading between 0.81 and 2.46.
Tweenvest scores Marker Therapeutics, Inc. across four factors: quality 28/100, value 55/100. Its strongest factor is value.
MRKR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.18M
- Revenue (TTM)
- $2.69M
- P/E
- —
- EPS
- -0.47
- Dividend yield
- —
- Beta (5Y)
- 1.51
- 52-week high
- $2.46
- 52-week low
- $0.81
- Avg volume (3M)
- —
- Shares outstanding
- 16.67M
- Employees
- 5
- Next earnings
- —
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
- ISIN
- US57055L2060
- Founded
- 1999
- Listed since
- Jul 16, 2002
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.